Stock Evaluator: Aardvark Therapeutics, Inc. (AARD)

Aardvark Therapeutics, Inc. AARD

$0.92 -0.08 -7.74%
November 20, 2026 4:00:01 PM EST November 10, 2021 Volume: 241,067
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Commentary & Analysis


Financial Summary

Share Statistics AARD Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $20.2 $421.5 12%
Shares Out (Mil) 21.9 46.9 32%
Institutional Ownership 62.0% 82.0% 39%
Float (Mil) 12.3 49.2 22%
Beta na 0.68 na
Avg Daily Volume (000s) 392 347 54%
Price Change
(52-week)
(91.2%) 49.3% 5%
Growth AARD Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 6.4% na
Net Income (5yr) na (1.3%) na
EPS (5yr) na 15.1% na
Dividends (5yr) na 0.0% na
Cash Flow (5yr) na (15.0%) na
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 7 6 9
Current EPS ($0.801) ($3.330) ($2.340)
Month Ago EPS ($0.684) ($3.029) ($2.351)
# Rev Up 1 0 0
# Rev Down 1 1 1
Three Months Ago EPS ($0.740) ($3.168) ($2.782)
Year/Year Chg (9.0%) 13.5% (18.8%)
Financials AARD Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $275 na
Net Income (TTM) (Mil) ($73) ($11) 13%
EPS (TTM) ($3.332) ($0.700) 10%
Operating Cash Flow (TTM) (Mil) ($67) ($7) 8%
Net Cash Flow (TTM) (Mil) $21 $1 63%
Long-Term Debt (Q1) (Mil) $0 $6 12%
Enterprise Value (Q1) (Mil) ($31) $331 1%
Valuation AARD Industry
Median
Percentile
(All Stocks)
P/B 0.35 2.08 9%
P/E na 20.9 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.1 na
Ratios AARD Industry
Median
Percentile
(All Stocks)
Gross Margin na 69.5% na
Net Margin na 3.6% na
ROA (73.5%) (23.8%) 7%
ROE (80.9%) (24.2%) 10%
Liabilities to Assets 11.1% 31.6% 7%
F-Score 1 3 1%

Passing Stock Screens

As of 11/20/2026, from a list of 60 stock screening strategies, AARD meetings the criteria of 1 screen:

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors